Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irofulven - Lantern Pharma/Oncology Venture US

Drug Profile

Irofulven - Lantern Pharma/Oncology Venture US

Alternative Names: 6-HMAF; 6-hydroxymethylacylfulvene; E 7850; HMAF; Irofulven-1; LP 100; MGI 114

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Dainippon Sumitomo Pharma; Eisai Co Ltd; Lantern Pharma; Oncology Venture A/S
  • Class Antineoplastics; Sesquiterpenes; Small molecules
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer; Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 18 Oct 2018 Oncology Venture initiates enrolment in a phase II trial for Prostate cancer in Denmark (NCT03643107) (EudraCT2017-003549-72)
  • 04 Sep 2018 Oncology Venture plans a phase II trial for prostate cancer
  • 01 Sep 2018 Phase-II clinical trials in Prostate cancer (Hormone refractory, Combination therapy, Second-line therapy or greater, Metastatic disease) in Denmark (IV) (NCT03643107) (EudraCT2017-003549-72)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top